Literature DB >> 11559916

What is the true fetal loss rate in pregnancies affected by trisomy 21 and how does this influence whether first trimester detection rates are superior to those in the second trimester?

K Spencer.   

Abstract

Mesh：

Year:  2001        PMID： 11559916     DOI： 10.1002/pd.134

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN： 0197-3851            Impact factor:   3.050


× No keyword cloud information.
  10 in total

1.  Trisomy recurrence: a reconsideration based on North American data.

Authors:  Dorothy Warburton; Louis Dallaire; Maya Thangavelu; Lori Ross; Bruce Levin; Jennie Kline
Journal:  Am J Hum Genet       Date:  2004-07-08       Impact factor: 11.025

2.  Tumorigenesis in Down's syndrome: big lessons from a small chromosome.

Authors:  Dean Nižetić; Jürgen Groet
Journal:  Nat Rev Cancer       Date:  2012-09-21       Impact factor: 60.716

3.  Perinatal loss of Ts65Dn Down syndrome mice.

Authors:  Randall J Roper; Heidi K St John; Jessica Philip; Ann Lawler; Roger H Reeves
Journal:  Genetics       Date:  2005-09-19       Impact factor: 4.562

4.  Cardiovascular development and survival during gestation in the Ts65Dn mouse model for Down syndrome.

Authors:  Candice G Lorandeau; Lauren A Hakkinen; Clara S Moore
Journal:  Anat Rec (Hoboken)       Date:  2010-11-16       Impact factor: 2.064

5.  A Cost-Effectiveness Analysis of Screening Strategies Involving Non-Invasive Prenatal Testing for Trisomy 21.

Authors:  Shuxian Wang; Kejun Liu; Huixia Yang; Jingmei Ma
Journal:  Front Public Health       Date:  2022-05-31

6.  Down syndrome critical region-1 is a transcriptional target of nuclear factor of activated T cells-c1 within the endocardium during heart development.

Authors:  Hai Wu; Shih-chu Kao; Tomasa Barrientos; Scott H Baldwin; Eric N Olson; Gerald R Crabtree; Bin Zhou; Ching-Pin Chang
Journal:  J Biol Chem       Date:  2007-08-10       Impact factor: 5.157

7.  Rapid testing versus karyotyping in Down's syndrome screening: cost-effectiveness and detection of clinically significant chromosome abnormalities.

Authors:  Jean Gekas; David-Gradus van den Berg; Audrey Durand; Maud Vallée; Hajo Izaäk Johannes Wildschut; Emmanuel Bujold; Jean-Claude Forest; François Rousseau; Daniel Reinharz
Journal:  Eur J Hum Genet       Date:  2010-09-15       Impact factor: 4.246

8.  Understanding the basis for Down syndrome phenotypes.

Authors:  Randall J Roper; Roger H Reeves
Journal:  PLoS Genet       Date:  2006-03       Impact factor: 5.917

9.  Brief report: isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration.

Authors:  Aoife Murray; Audrey Letourneau; Claudia Canzonetta; Elisavet Stathaki; Stefania Gimelli; Frederique Sloan-Bena; Robert Abrehart; Pollyanna Goh; Shuhui Lim; Chiara Baldo; Franca Dagna-Bricarelli; Saad Hannan; Martin Mortensen; David Ballard; Denise Syndercombe Court; Noemi Fusaki; Mamoru Hasegawa; Trevor G Smart; Cleo Bishop; Stylianos E Antonarakis; Jürgen Groet; Dean Nizetic
Journal:  Stem Cells       Date:  2015-06       Impact factor: 6.277

10.  Molecular Characterization of Down Syndrome Embryonic Stem Cells Reveals a Role for RUNX1 in Neural Differentiation.

Authors:  Tomer Halevy; Juan-Carlos Biancotti; Ofra Yanuka; Tamar Golan-Lev; Nissim Benvenisty
Journal:  Stem Cell Reports       Date:  2016-09-08       Impact factor: 7.765
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.